Table 1 Background characteristics and pathological findings of the patients
From: The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
Characteristic | Total n=1410 | MSC-positive n=648 | MSC-negative n=762 | p-value |
|---|---|---|---|---|
Age | 62.4+12.2 | 62.8+12.0 | 62.1+12.3 | 0.279 |
Sex | 0.975 | |||
Male | 958 (67.9) | 440 (67.9) | 518 (68.0) | |
Female | 452 (32.1) | 208(32.1) | 244 (32.0) | |
Surgical procedures | <0.001 | |||
TG | 553 (39.2) | 311 (48.0) | 242 (31.8) | |
DG | 764 (54.2) | 334 (51.5) | 430 (56.4) | |
PG | 18 (1.3) | 2 (0.3) | 16 (2.1) | |
PPG | 75 (5.3) | 1 (0.2) | 74 (9.7) | |
Splenectomy | <0.001 | |||
Yes | 354 (25.1) | 241 (37.2) | 113 (14.8) | |
No | 1056 (74.9) | 407 (62.8) | 649 (85.2) | |
Main locatoin of the tumor | 0.019 | |||
U | 340 (24.1) | 157 (24.2) | 183 (24.0) | |
M | 620 (44.0) | 253 (39.0) | 367 (48.2) | |
L | 445 (31.6) | 234 (36.1) | 211 (27.7) | |
Whole | 5 (0.3) | 4 (0.6) | 1 (0.1) | |
Tumor diameter (mm) | 63.1 (37.5) | 75.5 (40.5) | 52.5 (31.1) | <0.001 |
Macroscopic type | <0.001 | |||
0 | 478 (33.9) | 52 (8.0) | 426 (55.9) | |
I | 64 (4.5) | 27 (4.2) | 37 (4.9) | |
II | 365 (25.9) | 233 (36.0) | 132 (17.3) | |
III | 371 (26.3) | 246 (38.0) | 125 (16.4) | |
IV | 100 (7.1) | 78 (12.0) | 22 (2.9) | |
V | 32 (2.3) | 12 (1.8) | 20 (2.6) | |
Histological type | 0.182 | |||
Differenteitated | 517 (36.7) | 225 (34.7) | 292 (38.3) | |
Undifferentiated | 893 (63.3) | 423 (65.3) | 470 (61.7) | |
UICC 8th | ||||
Tumor invasion | <0.001 | |||
T2 (muscuralis) | 412 (29.2) | 33 (5.1) | 379 (49.7) | |
T3 (sub serosa) | 492 (34.9) | 217 (33.5) | 275 (36.1) | |
T4a (serosa exposed) | 499 (35.4) | 391 (60.3) | 108 (14.2) | |
T4b (serosa infiltrating) | 7 (0.5) | 7 (1.1) | 0 | |
Pathological N factor | <0.001 | |||
N0 | 529 (37.5) | 164 (25.3) | 365 (47.9) | |
N1 | 287 (20.4) | 121 (18.7) | 166 (21.8) | |
N2 | 266 (18.9) | 141 (21.8) | 125 (16.4) | |
N3a | 228 (16.2) | 144 (22.2) | 84 (11.0) | |
N3b | 100 (7.1) | 78 (12.0) | 22 (2.9) | |
Pathological stage | <0.001 | |||
StageIB | 219 (15.5) | 14 (2.2) | 205 (26.9) | |
StageIIA | 263 (18.7) | 55 (8.5) | 208 (27.3) | |
StageIIB | 309 (21.9) | 158 (24.4) | 151 (19.8) | |
StageIIIA | 322 (22.8) | 201 (31.0) | 121 (15.9) | |
StageIIIB | 197 (14.0) | 140 (21.6) | 57 (7.5) | |
StageIIIC | 100 (7.1) | 80 (12.3) | 20 (2.6) | |
Adjuvant chemotherapy | ||||
Yes | 353 (25.0) | 220 (34.0) | 133 (17.5) | <0.001 |
No | 1055 (74.8) | 427 (65.9) | 628 (82.4) | |
Unknown | 2 (0.1) | 1 (0.1) | 1 (0.1) | |